Bulletin
Investor Alert

March 12, 2021, 10:32 a.m. EST

TUESDAY DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Decision Diagnostics Corp. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Decision Diagnostics Corp. (DECN)

or Cancel Already have a watchlist? Log In

Los Angeles, California, Mar 12, 2021 (Newsfile Corp via COMTEX) -- Los Angeles, California--(Newsfile Corp. - March 12, 2021) - The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Decision Diagnostics Corp. /zigman2/quotes/210557282/delayed DECN +21.21% ("Decision Diagnostics" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between March 3, 2020 and December 17, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before March 16, 2021.

If you are a shareholder who suffered a loss, click here to participate .

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com , or by email at brian@schallfirm.com .

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Decision Diagnostics failed to develop a viable COVID-19 test in any form, let alone a test that could detect the virus in less than one minute. The Company was not capable of meeting the FDA's EUA testing requirements for its purported COVID-19 test. Despite this inability to meet FDA requirements, the Company touted an unrealistic time to market for its tests. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Decision Diagnostics, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com

SOURCE:

The Schall Law Firm

Corporate Logo

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/76996

COMTEX_382598522/2523/2021-03-12T10:31:44

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

copyright (c) newsfile corp. 2021. all rights reserved

/zigman2/quotes/210557282/delayed
US : U.S.: OTC
$ 0.0040
+0.0007 +21.21%
Volume: 256,500
July 30, 2021 3:40p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$1.42 million
Rev. per Employee
N/A
loading...

This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.